CAPLIN POINT LABORATORIES Financial Statement Analysis
|
||
The Revenues of CAPLIN POINT LABORATORIES have increased by 15.54% YoY .
The Earnings Per Share (EPS) of CAPLIN POINT LABORATORIES has increased by 21.40 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
CAPLIN POINT LABORATORIES Last 5 Annual Financial Results
[BOM: 524742|NSE : CAPLIPOINT]
Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
---|---|---|---|---|---|
Revenues | ₹1,467 Cr | ₹1,269 Cr | ₹1,061 Cr | ₹86,320 Cr | ₹649 Cr |
Expenses | ₹1,026 Cr | ₹875 Cr | ₹737 Cr | ₹60,313 Cr | ₹417 Cr |
Operating Profit (Excl OI) | ₹441 Cr | ₹395 Cr | ₹324 Cr | ₹26,007 Cr | ₹232 Cr |
Other Income | ₹57 Cr | ₹39 Cr | ₹28 Cr | ₹4,133 Cr | ₹19 Cr |
Interest | ₹0.78 Cr | ₹0.70 Cr | ₹1.59 Cr | ₹32 Cr | ₹0.58 Cr |
Depreciation | ₹45 Cr | ₹47 Cr | ₹37 Cr | ₹3,162 Cr | ₹23 Cr |
Profit Before Tax | ₹451 Cr | ₹386 Cr | ₹314 Cr | ₹26,946 Cr | ₹227 Cr |
Profit After Tax | ₹377 Cr | ₹308 Cr | ₹251 Cr | ₹21,508 Cr | ₹177 Cr |
Consolidated Net Profit | ₹376 Cr | ₹300 Cr | ₹242 Cr | ₹21,501 Cr | ₹177 Cr |
Earnings Per Share (Rs) | ₹60.18 | ₹49.57 | ₹39.56 | ₹32.03 | ₹28.42 |
PAT Margin (%) | 27.24 | 25.70 | 24.30 | 23.69 | 24.92 |
ROE(%) | 22.97 | 23.68 | 24.77 | 25.65 | 29.58 |
ROCE(%) | 26.92 | 26.85 | 28.77 | 28.82 | 33.35 |
Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 |
Key Financials |
||
Market Cap | : | ₹ 18,217.6 Cr |
Revenue (TTM) | : | ₹ 1,830.8 Cr |
Net Profit(TTM) | : | ₹ 496.8 Cr |
EPS (TTM) | : | ₹ 65.4 |
P/E (TTM) | : | 36.7 |
Industry Peers & Returns | 1W | 1M | 1Y |
CAPLIN POINT LABORATORIES | 0.2% | 13.4% | 84.1% |
SUN PHARMACEUTICAL INDUSTRIES | 1% | 4.6% | 47.5% |
CIPLA | -1.1% | -0.3% | 20.7% |
DR REDDYS LABORATORIES | 2.2% | 12.1% | 21.6% |
ZYDUS LIFESCIENCES | -2.7% | 0.8% | 43.8% |
DIVIS LABORATORIES | 1% | -3.2% | 59.3% |
MANKIND PHARMA | 0.8% | 12.8% | 52.4% |
TORRENT PHARMACEUTICALS | -1.5% | 5.9% | 55% |
LUPIN | 0.9% | 7.2% | 72.7% |
CAPLIN POINT LABORATORIES Revenues
[BOM: 524742|NSE : CAPLIPOINT]
Y-o-Y | 15.54 % |
5 Yr CAGR | 22.62 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹1,467 Cr | 15.54 | |
Mar2023 | ₹1,269 Cr | 19.61 | |
Mar2022 | ₹1,061 Cr | -98.77 | |
Mar2021 | ₹86,320 Cr | 13,206.82 | |
Mar2020 | ₹649 Cr | - |
CAPLIN POINT LABORATORIES Operating Profit
[BOM: 524742|NSE : CAPLIPOINT]
Y-o-Y | 11.66 % |
5 Yr CAGR | 17.41 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹441 Cr | 11.66 | |
Mar2023 | ₹395 Cr | 21.67 | |
Mar2022 | ₹324 Cr | -98.75 | |
Mar2021 | ₹26,007 Cr | 11,116.87 | |
Mar2020 | ₹232 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -3.38 % |
5 Yr CAGR | -4.26 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 30.03% | -3.38 | |
Mar2023 | 31.08% | 1.73 | |
Mar2022 | 30.55% | 1.39 | |
Mar2021 | 30.13% | -15.70 | |
Mar2020 | 35.74% | - |
CAPLIN POINT LABORATORIES Profit After Tax
[BOM: 524742|NSE : CAPLIPOINT]
Y-o-Y | 25.49 % |
5 Yr CAGR | 20.82 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹376 Cr | 25.49 | |
Mar2023 | ₹300 Cr | 23.76 | |
Mar2022 | ₹242 Cr | -98.87 | |
Mar2021 | ₹21,501 Cr | 12,077.96 | |
Mar2020 | ₹177 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 5.99 % |
5 Yr CAGR | 2.25 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 27.24 % | 5.99 | |
Mar2023 | 25.7 % | 5.76 | |
Mar2022 | 24.3 % | 2.57 | |
Mar2021 | 23.69 % | -4.94 | |
Mar2020 | 24.92 % | - |
CAPLIN POINT LABORATORIES Earnings Per Share (EPS)
[BOM: 524742|NSE : CAPLIPOINT]
Y-o-Y | 21.40 % |
5 Yr CAGR | 20.63 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹60 | 21.40 | |
Mar2023 | ₹50 | 25.30 | |
Mar2022 | ₹40 | 23.51 | |
Mar2021 | ₹32 | 12.70 | |
Mar2020 | ₹28 | - |
CAPLIN POINT LABORATORIES Return on Capital Employed (ROCE)
[BOM: 524742|NSE : CAPLIPOINT]
Y-o-Y | 0.26 % |
5 Yr CAGR | -5.21 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 26.92% | 0.26 | |
Mar2023 | 26.85% | -6.67 | |
Mar2022 | 28.77% | -0.17 | |
Mar2021 | 28.82% | -13.58 | |
Mar2020 | 33.35% | - |
CAPLIN POINT LABORATORIES Share Price vs Sensex
Current Share Price | : | ₹2,397.1 |
Current MarketCap | : | ₹ 18,217.6 Cr |
Updated EOD on | : | Dec 26,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
CAPLIN POINT LABORATORIES | 0.2% |
13.4% |
84.1% |
SENSEX | -2.1% |
-2% |
11.3% |
CAPLIN POINT LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 0.2% | 2.1% | 47.3% |
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
S&P BSE 500 | -2.2% | -0.7% | 18.8% |
S&P BSE 400 MIDSMALLCAP | -2.5% | 1.3% | 30.7% |
S&P BSE 250 SMALLCAP | -2.6% | 1.7% | 29.4% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 500 | -2.2% | -0.6% | 19.4% |
NIFTY500 MULTICAP 50:25:25 | -2.3% | 0.3% | 23% |
NIFTY MID SMALL400 | -2.5% | 2% | 30.1% |
NIFTY SMALLCAP250 | -2.5% | 2.3% | 31.6% |
You may also like the below Video Courses
FAQ about CAPLIN POINT LABORATORIES Financials
How the annual revenues of CAPLIN POINT LABORATORIES have changed ?
The Revenues of CAPLIN POINT LABORATORIES have increased by 15.54% YoY .
How the Earnings per Share (EPS) of CAPLIN POINT LABORATORIES have changed?
The Earnings Per Share (EPS) of CAPLIN POINT LABORATORIES has increased by 21.40 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs